The U.S., followed by Switzerland, had the highest average cost per day to stay in a hospital as of 2015. At that time the hospital costs per day in the U.S. were on average 5,220 U.S. dollars. In comparison, the hospital costs per day in Spain stood at an average of 424 U.S. dollars. Even Switzerland, also a very expensive country, had significantly lower costs than the United States.

Number of U.S. hospitals

The number of U.S. hospitals has decreased in recent years with some increase in 2017. There are several types of hospitals in the U.S. with different ownerships. In general there are more hospitals with a non-profit ownership in the U.S. than there are hospitals with state/local government or for-profit ownership.

U.S. hospital costs

Health care expenditures in the U.S. are among the highest in the world. By the end of 2019, hospital care expenditures alone across the U.S. are expected to exceed 1.2 trillion U.S. dollars. Among the most expensive medical conditions treated in U.S. hospitals are septicemia, osteoarthritis and live births. There are different ways to pay for hospital costs in the United States. Among all payers of U.S. hospital costs, Medicare and private payers are paying the largest proportion of all costs.

The graph displays the average hospital stay cost per inpatient day in the United States by hospital type from 1999 to 2022. The x-axis represents the years, ranging from 1999 to 2022, while the y-axis indicates the cost in dollars per inpatient day. The data is categorized into three types of hospitals: State/Local Government Hospitals, Non-Profit Hospitals, and For-Profit Hospitals.

In 1999, State/Local Government Hospitals had an average cost of $1,004.02 per inpatient day, which increased to $2,856.58 by 2022. Non-Profit Hospitals started with the highest costs at $1,139.49 in 1999 and rose to $3,166.58 in 2022, maintaining the highest costs among the three categories throughout the period. For-Profit Hospitals had the lowest starting cost at $999.03 in 1999 and reached $2,383.42 by 2022.

The data reveals that all hospital types experienced a consistent upward trend in costs over the 23-year period. Non-Profit Hospitals consistently had the highest costs, followed by State/Local Government Hospitals, and then For-Profit Hospitals. This upward trajectory highlights the increasing healthcare expenses in the United States across all types of hospitals.

In 2022, on average the expenses incurred by a non-profit hospitals for one inpatient day amounted to 3,167 U.S. dollars, compared to 2,383 U.S. dollars of expenses for for-profit hospitals. State or local government hospitals have costs somewhere in-between.

This statistic shows the average cost per pediatric hospital stay among patients aged 0 to 20 years in the U.S. in 2016, by diagnostic category. During this year, the average cost per stay for a circulatory system diagnosis was 56,300 U.S. dollars. In comparison, the average cost per stay for all pediatric stays was 7,800 U.S. dollars.

This statistic depicts the mean cost per day of hospital admission for mental and substance use disorders in the U.S. in 2016. According to the data, the mean daily cost for patients with a principal diagnosis of MSUD was 1,400 U.S. dollars.

Average Patient cost outcomes by ABF facility and work stream (Inpatients, Sub acute, Emergency Presentations and outpatient clinics) submitted to the Independent Health Pricing Authority

Russia Avg Consumer Price: Medical: Hospital Care Costs per Day data was reported at 1,985.580 RUB in Jan 2019. This records a decrease from the previous number of 2,123.330 RUB for Dec 2018. Russia Avg Consumer Price: Medical: Hospital Care Costs per Day data is updated monthly, averaging 2,037.960 RUB from Jan 2018 (Median) to Jan 2019, with 13 observations. The data reached an all-time high of 2,123.330 RUB in Dec 2018 and a record low of 1,954.890 RUB in Jan 2018. Russia Avg Consumer Price: Medical: Hospital Care Costs per Day data remains active status in CEIC and is reported by Federal State Statistics Service. The data is categorized under Russia Premium Database’s Prices – Table RU.PA023: Average Consumer Price: Health Improvement and Medical Services.

As of June 2023, the average health care fee for outpatients per day was highest for the treatment of neoplasms at around 3.1 thousand points, which equals about 31 thousand Japanese yen. Neoplasms treatment was also the most expensive inpatient medical care at over 8.3 thousand points per day. Medical fees in Japan are scored in points and distributed to patients at the cashier as a receipt. The ministry of health designates the score points of medical treatments according to the services and required techniques. Each point can be calculated as 10 yen and is used to determine the amount of money covered by health insurance available in the country.

BackgroundDiabetes imposes a substantial burden globally in terms of premature mortality, morbidity, and health care costs. Estimates of economic outcomes associated with diabetes are essential inputs to policy analyses aimed at prevention and treatment of diabetes. Our objective was to estimate and compare event rates, hospital utilization, and costs associated with major diabetes-related complications in high-, middle-, and low-income countries.Methods and FindingsIncidence and history of diabetes-related complications, hospital admissions, and length of stay were recorded in 11,140 patients with type 2 diabetes participating in the Action in Diabetes and Vascular Disease (ADVANCE) study (mean age at entry 66 y). The probability of hospital utilization and number of days in hospital for major events associated with coronary disease, cerebrovascular disease, congestive heart failure, peripheral vascular disease, and nephropathy were estimated for three regions (Asia, Eastern Europe, and Established Market Economies) using multiple regression analysis. The resulting estimates of days spent in hospital were multiplied by regional estimates of the costs per hospital bed-day from the World Health Organization to compute annual acute and long-term costs associated with the different types of complications. To assist, comparability, costs are reported in international dollars (Int$), which represent a hypothetical currency that allows for the same quantities of goods or services to be purchased regardless of country, standardized on purchasing power in the United States. A cost calculator accompanying this paper enables the estimation of costs for individual countries and translation of these costs into local currency units. The probability of attending a hospital following an event was highest for heart failure (93%–96% across regions) and lowest for nephropathy (15%–26%). The average numbers of days in hospital given at least one admission were greatest for stroke (17–32 d across region) and heart failure (16–31 d) and lowest for nephropathy (12–23 d). Considering regional differences, probabilities of hospitalization were lowest in Asia and highest in Established Market Economies; on the other hand, lengths of stay were highest in Asia and lowest in Established Market Economies. Overall estimated annual hospital costs for patients with none of the specified events or event histories ranged from Int$76 in Asia to Int$296 in Established Market Economies. All complications included in this analysis led to significant increases in hospital costs; coronary events, cerebrovascular events, and heart failure were the most costly, at more than Int$1,800, Int$3,000, and Int$4,000 in Asia, Eastern Europe, and Established Market Economies, respectively.ConclusionsMajor complications of diabetes significantly increase hospital use and costs across various settings and are likely to impose a high economic burden on health care systems. Please see later in the article for the Editors' Summary

With global estimates of 15 million cases of sepsis annually, together with a 24% in-hospital mortality rate, this condition comes at a high cost to both the patient and to the health services delivering care. This translational research determined the cost-effectiveness of state-wide implementation of a whole of hospital Sepsis Pathway in reducing mortality and/or hospital admission costs from a healthcare sector perspective, and report the cost of implementation over 12-months. A non-randomised stepped wedge cluster implementation study design was used to implement an existing Sepsis Pathway (“Think sepsis. Act fast”) across 10 of Victoria’s public health services, comprising 23 hospitals, which provide hospital care to 63% of the State’s population, or 15% of the Australian population. The pathway utilised a nurse led model with early warning and severity criteria, and actions to be initiated within 60 minutes of sepsis recognition. Pathway elements included oxygen administration; blood cultures (x2); venous blood lactate; fluid resuscitation; intravenous antibiotics, and increased monitoring. At baseline there were 876 participants (392 female (44.7%), mean 68.4 years); and during the intervention, there were 1,476 participants (684 female (46.3%), mean 66.8 years). Mortality significantly reduced from 11.4% (100/876) at baseline to 5.8% (85/1,476) during implementation (p>0.001). Respectively, at baseline and intervention the average length of stay was 9.1 (SD 10.3) and 6.2 (SD 7.9) days, and cost was $AUD22,107 (SD $26,937) and $14,203 (SD $17,611) per patient, with a significant 2.9 day reduction in length of stay (-2.9; 95%CI -3.7 to -2.2, p

The projected average per capita daily income for 2010 was USD 0.68 in rural areas and USD 1.55 in urban areas. PEP costs were calculated as: ((Cost per dose+(days lost per dose * daily income))*clinic visits;§: Scenario with government providing PEP to bite patient free-of-charge;‡: Scenario with government providing PEP to bite patient free-of-charge from local health facilities (i.e. not only at district hospitals).ςThis regimen requires 4 hospital visits and therefore is equivalent in travel costs to the reduced Thai Red Cross ID regimen that uses less vaccine (0.1 ml/injection).

In fiscal year 2021/2022, a standard hospital stay in Canada cost on average 7,803 Canadian dollars. This is the cost for the hospital to treat the average acute inpatient that year. Cost for a hospital stay ranged from 6,620 in Ontario to 13,647 in the Northwest Territories.

BackgroundThere is scarce information on patients with secondary heart failure diagnosis (sHF). We aimed to compare the characteristics, burden, and outcomes of sHF with those with primary HF diagnosis (pHF).MethodsRetrospective, observational study on patients ≥18 years with emergency department (ED) visits during 2018 with pHF and sHF in ED or hospital (ICD-10-CM) diagnostic codes. Baseline characteristics, 30-day and 1-year mortality, readmission and re-ED visit rates, and costs were compared between sHF and pHF.ResultsOut of the 797 patients discharged home from the ED, 45.5% had sHF, and these presented lower 1-year hospitalization, re-ED visit rates, and costs. In contrast, out of the 2,286 hospitalized patients, 55% had sHF and 45% pHF. Hospitalized sHF patients had significantly (p < 0.01) greater comorbidity, lower use of recommended HF therapies, longer length of stay (10.8 ± 10.1 vs. 9.7 ± 7.9 days), and higher in-hospital and 1-year mortality (32 vs. 25.8%) with no significant differences in readmission rates and lower 1-year re-ED visit rate. Hospitalized sHF patients had higher total costs (€12,262,422 vs. €9,144,952, p < 0.001), mean cost per patient-year (€9,755 ± 13,395 vs. €8,887 ± 12,059), and average daily cost per patient.ConclusionHospitalized sHF patients have a worse initial prognosis, greater use of healthcare resources, and higher costs.

BackgroundDiabetes is a severe challenge to global public health since it is a leading cause of morbidity, mortality, and rising healthcare costs. 3.0 million Ethiopians, or 4.7% of the population, had diabetes in 2021. Studies on the chronic complications of diabetes in Ethiopia have not been conducted in lower-level healthcare facilities, so the findings from tertiary hospitals do not accurately reflect the issues with chronic diabetes in general hospitals. In addition, there is a lack of information and little research on the complications of chronic diabetes in Ethiopia. The objective of this study was to assess the degree of chronic diabetes complications and associated factors among diabetic patients presenting to general hospitals in the Tigray area in northern Ethiopia.MethodsAs part of a multi-centre cross-sectional study, 1,158 type 2 diabetes (T2D) patients from 10 general hospitals in the Tigray region were randomly chosen. An interviewer-administered questionnaire, a record review, and an SPSS version 20 analysis were used to collect the data. All continuous data were presented as mean standard deviation (SD), while categorical data were identified by frequencies. Using a multivariable logistic regression model, the factors associated with chronic diabetes complications among T2D diabetic patients were found, and linked factors were declared at p 0.05.ResultsFifty-four of people with diabetes have chronic problems. Hypertension (27%) eye illness, renal disease (19.1%), and hypertension (27%) eye disease were the most common long-term effects of diabetes. Patients with chronic diabetes complications were more likely to be older than 60, taking insulin and an OHGA (Oral Hyperglycemic Agent) (AOR = 3.00; 95% CI 1.73, 5.26), having diabetes for more than five years, taking more than four tablets per day (AOR = 1.63; 95% CI 1.23,2.15), and having high systolic and diastolic blood pressure. Patients with government employment (AOR = 0.48; 95% CI 0.26, 0.90), antiplatelet drug use (AOR = 0.29; 95% CI 0.16, 0.52), and medication for treating dyslipidemia (AOR = 0.54; 95% CI 0.35, 0.84), all had a decreased chance of developing a chronic diabetes problem.ConclusionAt least one chronic diabetic complication was present in more than half of the patients in this study. Chronic diabetes problems were related to patients’ characteristics like age, occupation, diabetes treatment plan, anti-platelet, anti-dyslipidemia medicine, duration of diabetes, high Systolic BP, high Diastolic BP, and pill burden. To avoid complications from occurring, diabetes care professionals and stakeholders must collaborate to establish appropriate methods, especially for individuals who are more likely to experience diabetic complications.

Study design, setting, population, sampling We conducted a landscape evaluation involving stakeholders in Africa (Ethiopia, Kenya, Nigeria, South Africa) and South Asia (India – five states of Delhi; Bihar, Uttar Pradesh, Telangana and Madhya Pradesh) on CC availability and use from 1 July 2022 to 31 December 2022. We used a mixed methods study design to understand the complexity of CC availability and use across these LMICs. We selected a geographically and culturally diverse countries with high annual preterm births (~200,000). The selection of stakeholders within each focus country was by convenience and/or purposive sampling. We selected health facilities providing care for preterm infants and were able to provide the data required to achieve the study's objectives. Proximity and ease of data collection was also factored into selection by research teams. Data collection Qualitative The research teams conducted key informant interviews and focus group discussions (FGD's) with stakeholders in newborn health. The interviews with healthcare providers sought to explore their experience of using CC as a treatment for AOP. Interviews with WHO and Ministry of Health officials sought to understand current global and national health policies and CC's inclusion in the essential drug list for using CC to treat AOP. Interviews with major drug suppliers and distributors of CC aimed to determine the current local market pricing of CC and its alternatives within and between countries. Also, to evaluate the factors determining the end-customer price of CC. The available average end-customer price per country was used to determine the daily cost of managing AOP for aminophylline and CC. We compared the average daily cost between aminophylline and cc for both public and private hospitals in each country. The dosing regimen for CC was a loading dose of 20 mg/kg/dose and a daily maintenance dose of between 5 to 10 mg/kg/day. The dosing regimen for aminophylline was a loading dose of 6 mg/kg administered intravenously (IV), followed by a maintenance dose of 2.5 mg/kg/dose/IV administered every 8 hours. Interviews and FGD's were done in person or virtually over video or audio teleconferencing based on the preferences of the participants. All interviews were conducted in English. teams were situated in each country of focus and had previous training and experience conducting qualitative interviews and FGDs and in qualitative data analysis. The interviews and FGDs were semi structured using guide with a set of open-ended questions, in a set order and allowing for in-depth insights into the subject area. These guides were pilot tested across the 3 countries prior to data collection. Quantitative Additional interviews were conducted using standard questionnaires and had been piloted and refined in these settings prior to being used for data collection.The research team surveyed 107 providers: 20 from Ethiopia, 18 from India, 23 from Kenya, 28 from Nigeria, and 18 from South Africa. Providers were from 45 private or public health facilities across the five study countries. Of these, 12 (27%) were primary or secondary public, 7 (16%) were primary or secondary private, 25 (56%) were tertiary public, and 1 (2%) tertiary private Demand forecast for caffeine citrate. A demand forecast was conducted to determine the amount of CC needed per country. Using data from demographic health survey data from each country, we estimated the proportion of infants who would be eligible for CC treatment. Given AOP risk can be as high as 80% in preterm infants with birthweight ≤1500g (very low birth weight (VLBW)), we estimated that all VLBW infants met eligibility criteria for treatment with CC. We limited this forecast to public facilities where limited government funding constrains drug availability. We applied country-specific policies and assumptions to determine the percentage of VLBW infants who received or had a missed opportunity for CC treatment. These assumptions included, availability of CC, VLBW infants born in secondary facilities will be transferred to a tertiary center capable of providing AOP treat; some transfers will be unsuccessful and even when successful, AOP treatment will be unavailable. Data management and analysis All interviews were transcribed verbatim by an experienced transcriber. Authors reviewed the interview transcripts for errors. A coding framework was generated, and an emergent thematic analysis approach was used to analyze the data, to identify patterns and themes. Descriptive statistics were used to summarize the quantitative data. Apnea of prematurity (AOP) is a common complication among preterm infants (<37 weeks gestation), globally. However, access to caffeine citrate (CC) that is a proven safe and effective treatment in high income countries is largely unavailable in low-and-middle income countries, where most preterm infants are born. Therefore, the overall aim of this study was to describe the ...

aInpatient, day-case and outpatient cost data were collected for both locations, Nottingham and Leicester.bAdjusted by age, sex, hospital location (Leicester), and baseline utility, permanent care home residence, Charlson co-morbidity (scores 2–3 and ≥4), and higher risk of future health problems at admission (≥4 on Identification of Senior at Risk (ISAR) tool). A GLM model (family—gamma, link—0.45) was applied.cOLS was applied (adjustment covariates as above, except care home residence at baseline).dFrom CEAC (Fig 1) we know that 95% CI for ICER is £13,900-∞.Complete-case cost-effectiveness analysis (mean cost in £ / mean QALY, 95% CI).

Average service probability ravg of three periods.

This statistic depicts the expenses per inpatient stay garnered by community hospitals in the United States from 1975 to 2019. In 2019, the expenses for community hospitals located in the country totaled some 14,101 U.S. dollars per inpatient stay. The majority of registered hospitals in the United States are considered community hospitals.

Multivariate Regression Analysis.

Dental crown production was the most expensive medical service in Russia in 2020, with an average consumer price reaching nearly 4.6 thousand Russian rubles per unit. Furthermore, one day of medical treatment in a sanatorium cost over three thousand Russian rubles. General blood tests, dentist consultations, and physiotherapeutic treatments had an average price of under 500 Russian rubles.